Foghorn Therapeutics (FHTX) Total Non-Current Liabilities (2020 - 2026)

Foghorn Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $298.1 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 6.69% year-over-year to $298.1 million; the TTM figure through Mar 2026 stood at $298.1 million (down 6.69% YoY), while the FY2025 annual figure was $306.0 million, down 7.12% from the prior year.
• Total Non-Current Liabilities was $298.1 million for Q1 2026 at Foghorn Therapeutics, down from $306.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $415.8 million in Q1 2022 to a low of $294.0 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $357.8 million across 5 years, with a median of $367.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 290.36% in 2022, then dropped 10.29% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $404.7 million in 2022, then decreased by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then fell by 7.12% to $306.0 million in 2025, then slipped by 2.59% to $298.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $298.1 million (Q1 2026), $306.0 million (Q4 2025), and $294.0 million (Q3 2025), per Business Quant data.